News und Analysen
ICON Reports Second Quarter 2024 Results
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the second quarter ended June 30, 2024.
CEO, Dr
Chemed Reports Second-Quarter 2024 Results
Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest
Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery
Charles River Laboratories International, Inc. (NYSE: CRL) and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that
ICON announces results of Annual General Meeting and changes to the Board of Directors
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on
Premier, Inc. to Report Fiscal 2024 Fourth-Quarter and Full-Year Results and Host Conference Call on August 20, 2024
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2024 fourth quarter and full year on Tuesday, August 20, 2024, at approximately 6:30 a.m. ET. The
Almirall’s H1 2024 Results: Almirall Delivers Strong Performance in the First Half of 2024, Achieving Net Sales Growth of 6.7% Driven by Its European Dermatology Business and Accelerating Biologics Sales
Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first half of 2024. Almirall continued to deliver strong sales growth in
Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7th, before the market opens. A conference call has been scheduled
Acadia Healthcare Announces Date for Second Quarter 2024 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2024 results on Wednesday, July 31, 2024, after the close of the market. Acadia will conduct a
ICON Recognised for Leadership Position in Clinical Research Industry and as Socially Responsible Employer
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2024 with a number of leading business and industry
NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe Atopic Dermatitis in the NHS England in Eligible Adolescents and Adults
Almirall S.A. (BME: ALM), a global biopharmaceutical company dedicated to medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has recommended
Charles River to Perform Plasmid Manufacturing for AAVantgarde
Charles River Laboratories International, Inc. (NYSE: CRL) and AAVantgarde today announced a contract development and manufacturing organization (CDMO) agreement to produce Good Manufacturing
ICON plc Schedules Second Quarter 2024 Earnings Conference Call
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the second quarter 2024 after the
Chemed To Report Second-Quarter 2024 Earnings July 24, Related Conference Call To Be Held On July 25
Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2024, on Wednesday, July 24, 2024, following the close of trading on the
Novocure to Report Second Quarter 2024 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management
Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year1
Almirall, a global pharmaceutical company dedicated to medical dermatology, announced today new data from the real-world evidence clinical study called “POSITIVE” demonstrating that Ilumetri®
Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus
Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and
LivaNova to Announce Second-Quarter 2024 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m. London time (8
Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive
Annual General Shareholders’ Meeting 2024: Sonova shareholders approve all motions of the Board of Directors
Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a multidisciplinary program, funded through a $1.3 million grant from the Foundation for Chemistry Research & Initiatives
LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the preliminary results for the unipolar patient cohort of the RECOVER clinical study, assessing the use of
Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville
Charles River Laboratories International, Inc. (NYSE: CRL) has announced the opening of a new Charles River Accelerator and Development Lab (CRADL®) facility on Chestnut Street in Somerville
Acadia Healthcare Celebrates Timberline Knolls’ “Every Bite a Battle” Awareness Program
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today honored the "Every Bite A Battle" program that was recently launched at its Timberline Knolls Residential Treatment Center in Lemont, Illinois